TSS
TNGX icon

Two Sigma Securities’s Tango Therapeutics TNGX Stock Holding History

Two Sigma Securities’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,069
Closed -$40.1K – 3486
2023
Q2 		$40.1K Buy
+12,069
New +$43.4K ﹤0.01% 2425

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Two Sigma Securities's TNGX Position: Q3 2023 in Review

Two Sigma Securities sold out of Tango Therapeutics (TNGX) in Q3 2023, closing a stake of 12,069 shares — an estimated $40.1K sold.

Two Sigma Securities first reported a position in TNGX in Q2 2023 and held it in 1 quarter. The position peaked at $40.1K in Q2 2023. 100 funds tracked by Wall St. Rank hold TNGX as of Q3 2023.

  • Two Sigma Securities reported no remaining Tango Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Securities sold 12,069 Tango Therapeutics shares in Q3 2023, an estimated $40.1K.
  • Two Sigma Securities first reported a position in Tango Therapeutics in Q2 2023 and held it in 1 quarter.
  • Two Sigma Securities's Tango Therapeutics position peaked at $40.1K in Q2 2023.
  • 100 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.